Markus Aebi

Corporate Officer/Principal at Institute of Microbiology

Consumer Services

Health Technology

Profile

Dr. Markus Aebi is Chief Scientific Officer at Malcisbo AG and a Professor at Institute of Microbiology.
Dr. Aebi was previously employed as a Principal by Swiss National Science Foundation.
He received his undergraduate degree from the California Institute of Technology and a doctorate degree from the University of Zurich.

Markus Aebi active positions

Companies	Position	Start
Institute of Microbiology	Corporate Officer/Principal	22/09/2011

All active positions of Markus Aebi

Former positions of Markus Aebi

Companies	Position	End
Swiss National Science Foundation	Corporate Officer/Principal	01/01/1994
Malcisbo AG Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland.	Founder	-

See the detail of Markus Aebi's experience

Training of Markus Aebi

California Institute of Technology	Undergraduate Degree
University of Zurich	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Markus Aebi's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Swiss National Science Foundation
Malcisbo AG Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland.	Health Technology